{
    "nctId": "NCT05892146",
    "briefTitle": "Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction",
    "officialTitle": "Strategy Therapy on Early Phase Cancer Therapeutics-Related Cardiac Dysfunction Patients",
    "overallStatus": "RECRUITING",
    "conditions": "Chemotherapeutic Toxicity, Cardiotoxicity, Heart Failure, Breast Cancer, Lymphoma",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Change in absolute global longitudinal strain value measured by left ventricular global peak systolic longitudinal strain",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who are newly diagnosed with breast cancer or lymphoma and never accepted anti-cancer therapy\n* Age 20-65 years old\n* Systolic blood pressure \u2265 110 mmHg\n\nExclusion Criteria:\n\n* End-stage renal disease (estimated Glomerulus Filtration Rate \\<15 mL/min/1.73 m2)\n* Echocardiography Baseline left ventricle ejection fraction \\< 50%\n* Allergy history to angiotensin receptor blockers\n* Life expectancy \\< 1 year\n* Pregnancy\n* Unwilling to participate in this clinical study",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}